The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...

IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

Eterna Therapeutics, Inc. (ERNA) announced Tuesday positive results from a preclinical study on the company's lead cell therapy ...

New data from proof-of-concept study provides roadmap for treatment of ovarian cancerCAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE ...

EXCLUSIVE: When Kevin Davies saw volunteers swabbing concert goers for the stem cell register, he never dreamed he'd be a ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Metastatic Pancreatic Cancer.

aService d'hépato-gastroentérologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels 1200, Belgium bLaboratory of Hepatogastroenterology, Institut de recherche ...

A combination of avutometinib and defactinib has been granted priority review by the FDA for the treatment of KRAS-mutant recurrent low-grade serous ovarian cancer. The FDA has accepted and ...

and treatment. The experience of a ruptured ovarian cyst varies greatly depending on factors like its size, contents, and whether it causes bleeding. Below are the common signs listed by Dr ...